Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
P414495-1mg | 1mg | In stock | $240.90 | |
P414495-5mg | 5mg | In stock | $549.90 | |
P414495-10mg | 10mg | In stock | $858.90 | |
P414495-25mg | 25mg | In stock | $1,716.90 | |
P414495-50mg | 50mg | In stock | $2,746.90 |
Glukagon Receptor Agonists
Synonyms | PF-06882961 | Danuglipron | 2230198-02-2 | Danuglipron [USAN] | DN9IUI24GP | (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid | 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | PF-06882961, a non-peptide agonist, activates the canonical G protein signaling activity only in the Glukagon-like peptide-1 (GLP-1) receptor with Trp33ECD. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of GLP-1 receptor |
Note | 卖完停产,不再备货 |
Product Description | Information PF-06882961 PF-06882961, a non-peptide agonist, activates the canonical G protein signaling activity only in the Glukagon-like peptide-1 (GLP-1) receptor with Trp33 ECD . Targets GLP-1 receptor In vitro PF-06882961 stimulates cAMP accumulation in CHO cells expressing both the human and monkey GLP-1Rs with comparable EC50 values. In contrast, PF-06882961 does not increase cAMP levels in cells expressing the mouse, rat, or rabbit GLP-1R. In vivo PF-06882961 potentiates glucose-stimulated insulin release and reduces food intake in monkeys. Cell Research(from reference) Cell lines:HEK293 cells Concentrations:1 μM Incubation Time:30 minutes |
ALogP | 1.4 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid |
---|---|
INCHI | InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1 |
InChi Key | HYBAKUMPISVZQP-DEOSSOPVSA-N |
Canonical SMILES | C1CN(CCC1C2=NC(=CC=C2)OCC3=C(C=C(C=C3)C#N)F)CC4=NC5=C(N4CC6CCO6)C=C(C=C5)C(=O)O |
Isomeric SMILES | C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F |
Alternate CAS | 2230198-02-2 |
PubChem CID | 134611040 |
Molecular Weight | 555.6 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2218501 | Certificate of Analysis | Jun 05, 2022 | P414495 |
H2218503 | Certificate of Analysis | Jun 05, 2022 | P414495 |
H2218504 | Certificate of Analysis | Jun 05, 2022 | P414495 |
H2218508 | Certificate of Analysis | Jun 05, 2022 | P414495 |
H2218546 | Certificate of Analysis | Jun 05, 2022 | P414495 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (179.98 mM); Ethanol: 100 mg/mL (179.98 mM); Water: Insoluble; |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H302:Harmful if swallowed |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P301+P312:IF SWALLOWED: call a POISON CENTER/doctor/... IF you feel unwell. |
1. Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, Underwood CR, Egebjerg T, Šenel P, Stewart GD et al.. (2020) Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists.. Mol Cell, 80 (3): (485-500.e7). [PMID:33027691] |
2. Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM et al.. (2022) A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.. J Med Chem, 65 (12): (8208-8226). [PMID:35647711] |